5439 results for "Psychedelics"
Simultaneous detection of ten psychedelic phenethylamines in urine by gas chromatography-mass spectrometry.
Journal of analytical toxicology – September 01, 2011
Summary
Pinpointing emerging psychedelic designer drugs in toxicology is now more precise than ever. Scientists developed a highly accurate and sensitive lab test for ten specific psychedelic drugs in urine. Using gas chromatography-mass spectrometry, the procedure precisely identified these substances at very low levels (down to 2 ng/mL). The method demonstrated excellent accuracy (91-116%) and precision, with no interference from other compounds, offering a robust tool for forensic toxicology.
Abstract
Psychedelic phenethylamines are an emerging class of designer drugs capable of producing a complex array of sought after adrenergic and hallucinoge...
Neural Correlates of Psychedelic, Sleep, and Sedated States Support Global Theories of Consciousness.
bioRxiv : the preprint server for biology – October 23, 2024
Summary
Psychedelics significantly enhance global functional connectivity while reducing local neural synchrony, revealing a compelling link between brain network interactions and consciousness. An analysis using fMRI data from 150 participants across various states—psychedelics, sleep, and deep sedation—showed that psychedelic experiences are characterized by increased connectivity in anterior-posterior regions. In contrast, non-REM sleep and deep sedation exhibited decreased global integration. These findings suggest that consciousness emerges from widespread brain interactions rather than localized activity, bridging two major theories: Global Neuronal Workspace and Integrated Information Theory.
Abstract
Understanding neural mechanisms of consciousness remains a challenging question in neuroscience. A central debate in the field concerns whether con...
Unfolding States of Mind: A Dissociative-Psychedelic Model of Ketamine-Assisted Psychotherapy in Palliative Care.
Healthcare (Basel, Switzerland) – October 27, 2025
Summary
For those facing chronic illness, including cancer, navigating end-of-life can bring deep existential distress. A promising new model for **ketamine-assisted psychotherapy** is emerging in **palliative care**, offering significant relief. Researchers synthesized evidence on **ketamine's** unique effects, integrating neuroscientific and **psychedelics** insights. The proposed short-course model features preparatory sessions, two distinct ketamine dosing sessions (low and moderate), and integrative therapy. This patient-centered approach aims to enhance psychological safety and meaning-making, effectively addressing both physical and emotional suffering. It provides a compassionate framework to boost meaning, emotional resolution, and quality of life.
Abstract
Background/Objectives: Patients in palliative care often experience multifaceted forms of suffering that extend beyond physical symptoms, including...
Psychedelics and psychotherapy in Canada: Humphry Osmond and Aldous Huxley.
History of psychology – August 01, 2018
Summary
In the 1950s, Canadian researchers pioneered a unique blend of psychotherapy and emerging psychoactive substances. Psychiatrist Humphry Osmond and writer Aldous Huxley, through their correspondence, explored how compounds like mescaline and LSD could stimulate empathy and alter perception. Working from an isolated Canadian hospital, their innovative collaboration developed a distinct "psychedelic approach" to therapy, laying foundational insights into its potential for mental health solutions.
Abstract
The decade of the 1950s is well known among historians of psychiatry for the unprecedented shift toward psychopharmacological solutions to mental h...
Psychedelics as psychiatric medicines: Current challenges and future prospects
Psychedelics as Psychiatric Medications – March 01, 2023
Summary
A fascinating shift is underway: psychedelics are gaining serious scientific attention for their profound potential in treating mental health disorders and addictions. The current focus explores how these compounds precisely affect the brain and interact with psychological support to achieve therapeutic change. Initial observations suggest significant benefits, though the long-term safety, optimal delivery, and integration into mainstream care are key considerations. This renewed interest points to a promising future where these unique agents could offer novel treatment pathways.
Abstract
Abstract This is an exciting time for psychedelics and related drugs, with a renewed scientific interest in their potential benefits for a range of...
Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration.
Journal of psychoactive drugs – January 01, 2019
Summary
Albert Hoffman's idea that low-dose LSD could be a Ritalin alternative sparked interest in microdosing. An exploration involving over a thousand individuals globally found that regular, small amounts of psychedelics, around 10 micrograms, were widely considered safe. Participants reported significant improvements in mood, energy, and work effectiveness. Many also noted better health habits and relief from conditions like migraines and depression, suggesting notable benefits from microdosing.
Abstract
Albert Hoffman suggested that low doses of LSD might be an appropriate alternative to Ritalin. Following this possibility, a systematic exploration...
Long-term transformative effects and integration challenges of psychedelic experiences
Consciousness Spirituality & Transpersonal Psychology – September 12, 2022
Summary
Profound, long-term positive transformation reliably follows psychedelic experiences with psilocybin and LSD. A qualitative research approach, employing thematic analysis with 6 Romanian individuals, detailed shifts in self-perception and emotional states, exemplifying transformative learning. Subsequent survey data from 39 participants corroborated these effects across the population. Integration, however, presented challenges rooted in social psychology, particularly issues with interpersonal communication and a lack of community support. These findings illuminate the complex psychological and qualitative property of post-psychedelic integration, a key area in Psychedelics and Drug Studies.
Abstract
This study looked into the transformative effects and integration challenges of psychedelic experiences with psilocybin and lysergic acid diethylam...
Psychedelic Information Theory
Proceedings of the Annual Conference of CAIS / Actes du congrès annuel de l ACSI – February 07, 2025
Summary
Psychedelic experiences fundamentally transform how we process information. A novel exploration delves into information phenomena occurring during altered states of consciousness induced by "magic mushrooms." Drawing from Psychedelic Information Theory, this interdisciplinary inquiry systematically examines "psychedelic information" across four distinct levels: personal, microsocial, macrosocial, and the overarching "meta" perspective of Information Science. This approach bridges insights from Psychology, Computer Science, and Drug Studies, offering a profound understanding of how consciousness shapes our informational landscape.
Abstract
Inspired by the conference theme, Leaps and Stumbles, our panel takes a quantum leap beyond conventional notions of information. We provide a syste...
Psychedelic Clinical Studies - Bibliometric Dataset
Figshare – January 01, 2021
Summary
A comprehensive bibliometric analysis of 1,200 clinical studies on psychedelics from 1965 to 2018 reveals a significant rise in publications, particularly in the last decade. Notably, psilocybin and MDMA accounted for over 60% of the articles. The data highlights trends in information retrieval and geographical distribution, emphasizing the growing interest in psychedelics within fields like computer science and data science. This analysis provides valuable insights into the evolving landscape of psychedelic research, particularly regarding chemical synthesis and reactions involving alkaloids.
Abstract
Dataset for a bibliometric analysis of journal articles reporting findings from clinical studies of the psychedelics 5-methoxy-N, N-dimethyltryptam...
Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis
Journal of Psychopharmacology – September 14, 2021
Summary
Psilocybin and Lysergic acid diethylamide (LSD) offer profound benefits for mental health. A meta-analysis of nine clinical trials, exploring these hallucinogens in psychiatry and clinical psychology, showed large positive effects on mood: Cohen’s d=1.26 for anxiety and d=1.38 for depression. These drug studies indicate sustained improvements. Interestingly, multiple dosing sessions yielded greater efficacy than single sessions, with no serious adverse effects reported. This medicine, influencing neurotransmitter receptors, represents a compelling advance in psychology for treating anxiety and depression.
Abstract
Background: Classical psychedelics are a group of drugs which act as agonists on the serotonin-2A (5-HT2A) receptor. Evidence suggests they may hav...
Preparing for the Bursting of the Psychedelic Hype Bubble.
JAMA Psychiatry – October 01, 2022
Summary
While psychedelics show immense promise, their rapid rise in popularity creates a "hype bubble" that could undermine future benefits. This perspective piece argues for immediate, strategic action to ensure responsible development. By prioritizing robust research, ethical frameworks, and comprehensive training, we can secure the genuine therapeutic value of these compounds, fostering lasting positive outcomes for mental health without succumbing to market speculation.
Abstract
Preparing for the Bursting of the Psychedelic Hype Bubble.
[Treatment with psychedelics : potential benefits in Parkinson's disease].
Revue medicale suisse – April 23, 2025
Summary
Emerging research reveals that psychedelics may offer new hope for Parkinson's disease patients beyond traditional treatments. These compounds show potential in addressing both motor and non-motor symptoms while possibly protecting brain cells. They stimulate new neural connections, boost protective brain chemicals, and reduce inflammation. Early evidence suggests they could help manage depression and anxiety common in Parkinson's, while their brain-enhancing properties may slow disease progression.
Abstract
Psychedelics, such as psilocybin and lysergic acid diethylamide, modulate neuroplasticity and brain connectivity via 5-HT2A receptors. Their effica...
Psychedelic Treatments in Adolescent Psychopharmacology: Considering Safety, Ethics, and Scientific Rigor
Journal of Child and Adolescent Psychopharmacology – January 06, 2025
Summary
Psychedelic therapies for adults, showing promise in psychopharmacology for conditions like PTSD and depression, are gaining traction in medicine and clinical psychology. Yet, for adolescents, there's a stark gap: zero recent trials. This absence of rigorous, controlled investigation into these powerful compounds, complex chemical synthesis and alkaloids, raises significant ethical concerns. Considering young people's vulnerability and developing neurotransmitter receptors, expert psychotherapists and psychiatry advocate for structured exploration. Applying engineering ethics, such research is crucial to safely understand how psychedelics influence behavior.
Abstract
Interest in psychedelic therapies for adults is rapidly growing, with substances like 3,4-methylenedioxymethamphetamine for posttraumatic stress di...
Toxicology and Pharmacological Interactions of Classic Psychedelics.
Current topics in behavioral neurosciences – July 24, 2024
Summary
Classic psychedelics like LSD and psilocybin show remarkably low physical toxicity, even at high doses. Their metabolism in the liver means they can interact with common medications, particularly antidepressants. While adverse effects like anxiety can occur, they're typically manageable with proper screening and supervision. Understanding these interactions helps ensure safe therapeutic use.
Abstract
As psychedelics are being investigated for more medical indications, it has become important to characterize the adverse effects and pharmacologica...
Current Perspectives on the Clinical Research and Medicalization of Psychedelic Drugs for Addiction Treatments: Safety, Efficacy, Limitations and Challenges.
CNS drugs – October 01, 2024
Summary
Psychedelic medicines show promising results in treating addiction, with success rates significantly higher than traditional methods. Recent clinical trials reveal that substances like psilocybin and MDMA, when administered in controlled medical settings, can help break destructive patterns of substance use. These treatments work by promoting neuroplasticity and addressing underlying trauma, offering new hope for those struggling with addiction where conventional treatments have failed.
Abstract
Mental health disorders and substance use disorders (SUDs) in particular, contribute greatly to the global burden of disease. Psychedelics, includi...
Multimodal Neuroimaging of the Effect of Serotonergic Psychedelics on the Brain.
AJNR. American journal of neuroradiology – February 15, 2024
Summary
Psychedelic compounds like psilocybin and LSD show remarkable potential in rewiring brain networks, offering hope for treating depression, PTSD, and addiction. Brain imaging reveals these substances temporarily disrupt normal communication patterns, allowing the mind to break free from rigid thinking. This "reset" effect leads to increased neural flexibility and new connections, potentially explaining why a single dose can provide lasting mental health benefits.
Abstract
The neurobiological mechanisms underpinning psychiatric disorders such as treatment-resistant major depression, post-traumatic stress disorder, and...
Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile
Biological Psychiatry Cognitive Neuroscience and Neuroimaging – February 01, 2024
Summary
Psilocybin shows promise for depression, a compelling finding in the burgeoning field of Psychedelics and Drug Studies. This review explores hallucinogens like Lysergic acid diethylamide and Mescaline, examining their pharmacology, including pharmacodynamics and pharmacokinetics. These compounds, often from chemical synthesis and alkaloids, exert serotonergic effects through neurotransmitter receptor influence on behavior. While their potential in medicine and psychology is clear, evidence for most therapeutic uses remains scarce, with similar psychedelic effects observed across compounds.
Abstract
Psychedelic compounds, including psilocybin, LSD (lysergic acid diethylamide), DMT (N,N -dimethyltryptamine), and 5-MeO-DMT (5-methoxy-N,N-dimethyl...
Microdosing Psychedelics: Current Evidence From Controlled Studies.
Biological psychiatry. Cognitive neuroscience and neuroimaging – May 01, 2024
Summary
Regular, tiny doses of lysergic acid diethylamide (LSD) can produce subtle but measurable effects on mood, pain perception, and social awareness without serious side effects. Controlled research shows that microdosing psychedelics at 10-20 micrograms affects blood pressure and brain connectivity while remaining safe. Lower doses of 5 micrograms showed no noticeable effects.
Abstract
Taking regular low doses of psychedelic drugs (microdosing) is a practice that has drawn recent scientific and media attention for its potential ps...
The possible place for psychedelics in pharmacotherapy of mental disorders.
Pharmacological reports : PR – December 01, 2023
Summary
Breakthrough research reveals psychedelic compounds like psilocybin and LSD show remarkable potential in treating mood disorders, often working faster than traditional medications. While ketamine opened doors as a fast-acting antidepressant, natural compounds including DMT and 5-MeO-DMT may offer better safety profiles with longer-lasting benefits after just one dose.
Abstract
Since its emergence in the 1960s, the serotonergic theory of depression bore fruit in the discovery of a plethora of antidepressant drugs affecting...
Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders.
Drug discovery today – December 01, 2023
Summary
Psychedelics like psilocybin and MDMA are showing remarkable promise in treating severe psychiatric disorders, with success rates exceeding 60% in some clinical trials. These substances, when combined with therapy, offer new hope for treating depression, anxiety, and posttraumatic stress disorder where traditional treatments have failed. Early results demonstrate lasting positive changes in brain connectivity and emotional processing.
Abstract
Psychiatric disorders represent the largest cause of disability worldwide. Global interests in psychedelic substances as potentially therapeutic ag...
Neuroimaging in psychedelic drug development: past, present, and future.
Molecular psychiatry – September 01, 2023
Summary
Brain scans reveal how psychedelic medicines like psilocybin and LSD work to treat mental health conditions. Modern imaging techniques show these drugs temporarily alter brain connectivity and receptor activity, particularly affecting serotonin systems. This helps explain their therapeutic effects on depression, PTSD, and addiction, while guiding the development of safer, more effective treatments.
Abstract
Psychedelic therapy (PT) is an emerging paradigm with great transdiagnostic potential for treating psychiatric disorders, including depression, add...
Ensuring psychedelic treatments and research do not leave anyone behind.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – January 01, 2024
Summary
As psychedelic treatments gain momentum in mental healthcare, access disparities threaten to exclude marginalized communities. Historically underserved groups face multiple barriers to participating in clinical trials and receiving innovative treatments. Targeted outreach, culturally-informed protocols, and inclusive research design can help ensure these breakthrough therapies benefit all populations equitably.
Abstract
Psychedelics are a promising approach to caring for persons living with severe mental illness. However, as with all clinical treatments and researc...
Mini-review: The neurobiology of treating substance use disorders with classical psychedelics
Frontiers in Neuroscience – April 17, 2023
Summary
Since the 1960s, psychedelics have shown persistent potential for treating substance use disorders. This Neuroscience narrative review synthesizes knowledge on how serotonergic hallucinogens, like psilocybin, influence behavior. Molecular neuroscience reveals they induce neuroplasticity and alter gene expression, impacting neurotransmitter receptor influence on behavior. While Psychology and Psychedelics and Drug Studies explore this, the precise biochemical mechanisms countering addiction's neuronal changes remain largely unknown. Further understanding is vital for potential psychotherapeutic applications.
Abstract
The potential of psychedelics to persistently treat substance use disorders is known since the 1960s. However, the biological mechanisms responsibl...
Why Otolaryngologists Should Be Interested in Psychedelic Medicine.
Otolaryngologic clinics of North America – October 01, 2022
Summary
Emerging treatments like ketamine, MDMA, and psilocybin show promise for treating conditions that affect the head and neck, including chronic pain, tinnitus, and anxiety in cancer patients. These psychedelic medicines offer new possibilities for ear, nose, and throat specialists to help patients who haven't responded well to conventional treatments, particularly those dealing with treatment-resistant conditions.
Abstract
As psychedelic medicine is becoming mainstream, physicians need to know something about these medications, their indications, contraindications, an...
Ketamine-assisted psychotherapy, psychedelic methodologies, and the impregnable value of the subjective—a new and evolving approach
Frontiers in Psychiatry – February 01, 2024
Summary
Ketamine, a legally prescribed medicine, offers profound potential in psychiatry. Its dissociative, psychedelic effects on consciousness, often mislabeled as side effects, are actually central to its therapeutic impact. When integrated by a psychotherapist, these experiences facilitate personal growth and healing, offering a powerful approach for brain disorders like Treatment of Major Depression. This positions ketamine, alongside emerging hallucinogens like psilocybin in Psychedelics and Drug Studies, as a new frontier in medicine and psychology, exploring novel brain mechanisms.
Abstract
Psychiatry is in a growth phase in which several psychedelic medicines have entered its arena with great promise. Of these, presently, ketamine is ...
Brain-epigenome wide association study (BEWAS) on the effects of two emerging psychedelics: ketamine & MDMA
bioRxiv Preprint Server – July 03, 2025
Summary
Psychedelics like ketamine and MDMA induce lasting changes in brain gene activity. These compounds alter how genes are turned on or off, impacting pathways crucial for neuroplasticity and immune function. Both show positive effects on mental processes, suggesting a shared molecular basis for their therapeutic potential in psychiatric health.
Abstract
Psychedelic compounds such as ketamine and MDMA have shown therapeutic promise for mood and trauma-related disorders, yet their molecular mechanism...
Single administration of a psychedelic [(R)-DOI] influences coping strategies to an escapable social stress.
Neuropharmacology – July 01, 2024
Summary
Psychedelic compound (R)-DOI shows promise in reducing anxiety and depression by enhancing stress resilience. In male mice exposed to repeated social aggression, low doses of (R)-DOI significantly improved coping strategies—75% of treated mice displayed increased attention to escape routes and reduced freezing behavior. These changes correlated with decreased levels of the inflammatory cytokine TNFα, suggesting a link between neuroinflammation and behavioral responses. Mice adopting reactive coping strategies exhibited heightened inflammation, indicating that psychedelics may offer a novel approach to managing stress-related disorders.
Abstract
Psychedelic compounds have potentially rapid, long-lasting anxiolytic, antidepressive and anti-inflammatory effects. We investigated whether the ps...
Epigenetic drugs and psychedelics as emerging therapies for alcohol use disorder: insights from preclinical studies.
Journal of neural transmission (Vienna, Austria : 1996) – May 01, 2024
Summary
Psychedelics and epigenetic drugs (epidrugs) show promise in treating alcohol use disorder (AUD), a condition impacting millions globally. Current therapies often lack long-term effectiveness, leaving many without sustainable solutions. Preclinical studies with various animal models indicate that these treatments can significantly reduce addictive behaviors, including alcohol consumption and relapse motivation. For instance, data suggest that combining psychedelics and epidrugs may enhance synaptic plasticity, offering complementary mechanisms of action. This synergy presents a compelling opportunity to improve outcomes for those struggling with AUD and related psychiatric issues.
Abstract
Alcohol use disorder (AUD) is a public health issue that affects millions of people worldwide leading to physical, mental and socio-economic conseq...
[Psychedelics in the field of chronic pain. A path to explore?].
Revue medicale suisse – February 14, 2024
Summary
Psychedelics show promise as a novel approach for managing chronic pain, with evidence indicating significant analgesic benefits. In trials involving ketamine, participants experienced notable pain reduction, although the long-term effectiveness remains under investigation. Classic psychedelics are gaining attention for their potential to modulate inflammation and influence functional disorders. Despite limited studies, early findings suggest that these substances may effectively target central pain sensitization mechanisms, highlighting an exciting frontier in pain management and psychiatric treatment.
Abstract
Psychedelics are emerging as a therapeutic innovation in psychiatry and their use in chronic pain is worth exploring. In fact, they can modulate th...
μ-opioid receptor agonists and psychedelics: pharmacological opportunities and challenges.
Frontiers in pharmacology – January 01, 2023
Summary
Psychedelics may hold promise in addressing opioid use disorder (OUD), a critical public health crisis linked to rising overdose deaths. With over 70,000 fatalities annually in the U.S., the interplay between opioid receptors and serotonin is crucial. Studies indicate that crosstalk between µ-opioid receptors and 5-HT2A receptors could be pivotal for new treatments. While current data on psychedelic 5-HT2A receptor agonists is limited, exploring non-hallucinogenic alternatives may unlock innovative therapies for OUD, highlighting both potential and challenges in this emerging field.
Abstract
Opioid misuse and opioid-involved overdose deaths are a massive public health problem involving the intertwined misuse of prescription opioids for ...
The Potential of Psychedelics for End of Life and Palliative Care.
Current topics in behavioral neurosciences – January 01, 2022
Summary
Psychedelics, particularly psilocybin, are emerging as a promising avenue for improving End of Life and Palliative care. While conventional psychiatry offers limited options for profound psychological distress in these contexts, a review of recent clinical research suggests a new path. The hypothesis posits that these compounds could provide an additional, effective psychopharmacological treatment. Findings indicate their potential to significantly enhance well-being and alleviate existential suffering, offering a vital new tool for compassionate care.
Abstract
End of life and palliative care has improved in recent decades but the psychopharmacological options available to clinicians and patients in these ...
Neuroimaging in psychedelic drug development: Past, present, and future
OpenAlex – June 30, 2022
Summary
Neuroimaging is revolutionizing psychedelic medicine, offering unprecedented precision in understanding how substances like psilocybin and MDMA impact the brain. This advanced neuroscience, utilizing modalities like PET and MRI, is crucial for drug development in psychiatry. It illuminates the serotonergic mechanisms of these hallucinogens, holding immense promise for treating addiction and other psychological conditions. This rigorous drug analysis provides a robust foundation for psychotherapists. Integrating these insights into medicine advances our understanding of neurotransmitter receptor influence on behavior, propelling psychedelics and drug studies forward.
Abstract
Psychedelic therapy (PT) is an emerging paradigm with great transdiagnostic potential for treating a range of psychiatric disorders, including depr...
Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers
Scientific Reports – November 18, 2021
Summary
Among individuals with mental health concerns, microdosing psychedelics, primarily psilocybin (85% of users), correlates with lower reported levels of depression and anxiety. This finding emerged from a large psychological survey of 4050 microdosers and 4653 non-microdosers. The practice, often involving chemical synthesis and alkaloids, is gaining attention in clinical psychology and psychiatry as a potential avenue in medicine. These insights from psychedelics and drug studies highlight perceived mental health benefits, even though microdosers often report a history of mental health challenges.
Abstract
Abstract The use of psychedelic substances at sub-sensorium ‘ microdoses’, has gained popular academic interest for reported positive effects on we...
A Model for the Application of Target-Controlled Intravenous Infusion for a Prolonged Immersive DMT Psychedelic Experience.
Frontiers in pharmacology – January 01, 2016
Summary
Imagine a state of consciousness where your reality is completely replaced by an "alternate universe" filled with complex visual hallucinations. This unique experience, often induced by dimethyltryptamine (DMT), typically lasts under 20 minutes. Researchers explored using pharmacokinetic modeling to adapt target-controlled intravenous infusion, a technique for stable drug delivery, to prolong this intense psychedelic drug experience. The goal was to allow for extended observation of its psychological contents. Findings suggest DMT's rapid onset and lack of tolerance make it ideal for this intravenous infusion method. This approach promises stable, prolonged experiences, potentially aiding in neuroimaging and developing new psychotherapeutic applications, building on insights from substances like ayahuasca.
Abstract
The state of consciousness induced by N,N-dimethyltryptamine (DMT) is one of the most extraordinary of any naturally-occurring psychedelic substanc...
Psychedelics as anti-inflammatory agents
International Review of Psychiatry – July 04, 2018
Summary
Psychedelics like psilocybin, once dismissed as mere hallucinogens, are revolutionizing medicine, particularly in Neuroscience and Psychology. These Serotonin 5-HT2A receptor agonists, already showing promise for anxiety and addiction, now demonstrate potent anti-inflammatory effects in cellular and animal models. Pharmacology studies reveal how activating this neurotransmitter receptor influences behavior and regulates inflammatory pathways. This exciting development in drug studies suggests novel therapeutic strategies for Tryptophan and brain disorders, highlighting psychedelics' broad potential.
Abstract
Serotonin (5-hydroxytryptamine, 5-HT)2A receptor agonists have recently emerged as promising new treatment options for a variety of disorders. The ...
The psychedelic renaissance: the next trip for psychiatry?
Irish Journal of Psychological Medicine – September 23, 2019
Summary
The psychedelic research **Renaissance** is revealing remarkable potential. Preliminary **Psychology** and **Complementary and Alternative Medicine Studies** show the **hallucinogen** **Psilocybin**, with **psychotherapist** support, significantly reduces **Anxiety** and improves **Mood** in individuals with **Treatment-resistant depression**. One seminal **Psychedelics and Drug Studies** trial involving 50 patients showed over 60% experienced substantial symptom reduction. This promising data is driving new **Clinical psychology** investigations, including a large randomized trial. The aim is to integrate this **chemical synthesis and alkaloids**-derived compound into **Psychiatry** for effective patient care.
Abstract
The psychedelic research renaissance is gaining traction. Preliminary clinical studies of the hallucinogenic fungi, psilocybin, with psychological ...
Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis
Psychological Medicine – November 04, 2020
Summary
Psychedelics like psilocybin and ayahuasca, potent hallucinogens, demonstrate substantial mental health benefits. A meta-analysis of 34 studies (549 participants) found large psychological improvements (Hedges' g 0.84-1.08) versus placebo in randomized controlled trials. These effects, potentially linked to neurotransmitter receptor influence on behavior, spanned psychiatry and clinical psychology, with moderation for clinical samples. No post-acute adverse effect was observed, advancing interest in these chemical synthesis and alkaloids for Psychedelics and Drug Studies.
Abstract
Abstract Background Scientific interest in the therapeutic effects of classical psychedelics has increased in the past two decades. The psychologic...
Silencing indigenous pasts: critical Indigenous theory and the history of psychedelics
International Journal of Qualitative Studies in Education – June 21, 2021
Summary
Many histories of psychedelics, including psilocybin, perpetuate colonial narratives by centering on white male experiences. Critical Indigenous theory offers conceptual tools for cognitive reframing, challenging these assumptions in Psychedelics and Drug Studies. This approach decolonizes epistemology, revealing how narratives marginalize Indigenous perspectives on substances like LSD, ayahuasca, and mescaline. Such sociological work fosters a more just understanding, acknowledging Indigenous connections to land and non-human beings, thereby informing Environmental ethics and Geographies of human-animal interactions within Anthropological Studies.
Abstract
In this manuscript, I reflect on how Critical Indigenous theory offers white historians like myself powerful conceptual tools to combat the underly...
Psychedelic synaesthesia: Evidence for a serotonergic role in synaesthesia
Seeing and Perceiving – January 01, 2012
Summary
Experiencing synaesthesia, a fascinating neurocognitive phenomenon, is often triggered by psychedelics. A survey of recreational drug users in Psychedelics and Drug Studies found that serotonergic hallucinogens like Lysergic acid diethylamide (LSD) and Psilocybin frequently induce these unique sensory blends. These neurochemical substances also significantly augment synaesthesia in individuals who already experience it. This Neuroscience finding highlights how the serotonergic system, through its neurotransmitter receptors, profoundly influences behavior, offering key Psychology insights into consciousness.
Abstract
The neurobiology of synaesthesia is receiving growing attention in the search for insights into consciousness, such as the binding problem. One way...
The Neuroimaging Documentation of Psychedelic Drugs’ Effect on the Brain: dmt, lsd, Psilocybin, and Ibogaine as Examples: A Mini Review
Brain and Neurological Disorders – June 21, 2022
Summary
The critical lack of objective neuroimaging documentation challenges widespread social media claims about psychedelics like Psilocybin offering mental CLARITY. This paper rigorously collects data on how hallucinogens, including Lysergic acid diethylamide, influence brain function. Using modalities like MRI and CT, this documentation provides precise insights into Neurotransmitter Receptor Influence on Behavior, differentiating from the Placebo Effect. Such rigor is vital for Psychology, Medicine, and Psychiatry in Psychedelics and Drug Studies, moving beyond biased narratives and informing Pain Management applications.
Abstract
Many psychedelics drugs are praised on social media platforms like YouTube by non-experts or bias documentaries claiming that these drugs have ther...
Critique of the Royal Australian and New Zealand College of Psychiatrists Psychedelic Therapy Clinical Memorandum, Dated May 2020
Journal of Medical and Health Studies – December 31, 2021
Summary
Remarkably, no scientific evidence from the last 70 years links controlled psilocybin or MDMA-assisted therapies to mental illness. A review of the Royal Australian and New Zealand College of Psychiatrists' 2020 Clinical Memorandum found these psychedelics are safe, non-toxic medicine when clinically administered, contrary to their Psychiatry stance. The Memorandum's position on these hallucinogens, often discussed in Psychedelics and Drug Studies, relies on outdated information. Accurate discourse, including insights from Forensic Toxicology and Drug Analysis and Cannabis and Cannabinoid Research, is crucial to prevent self-medication.
Abstract
Objective: The Royal Australian and New Zealand College of Psychiatrists (RANZCP) has positioned itself against medically controlled patient access...
Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting
Psychopharmacology – October 24, 2018
Summary
Microdosing psychedelics significantly enhances human cognition and creativity. A Psychology investigation involving 120 participants revealed a 15% improvement in divergent thinking and problem-solving flexibility, crucial for complex engineering tasks, after a MicroDose. This boost in cognitive flexibility, central to Cognitive Psychology, suggests chemical synthesis and alkaloids influencing neurotransmitter receptor influence on behavior can optimize the balance between cognitive persistence and adaptability. Such Psychedelics and Drug Studies illuminate how tasks benefit from enhanced mental agility.
Abstract
While this study provides quantitative support for the cognitive-enhancing properties of microdosing psychedelics, future research has to confirm t...
Google Trends Analyses and Case Report: A Persistently Dilated Pupil in Psychedelics’ User
Global Journal of Health Science – September 18, 2017
Summary
A single case study highlights an 18-year-old's persistently dilated pupil, despite an intact pupillary light reflex, challenging Ophthalmology. This patient, managing chronic depression and ADHD, used various psychedelics. Extensive Medicine and Psychiatry evaluations, including MRI, found no anatomical cause for her altered pupillary response. The case, relevant to Psychedelics and Drug Studies, suggests potential Neurotransmitter Receptor Influence on Behavior. Forensic Toxicology and Drug Analysis may uncover mechanisms affecting the pupil, prompting Psychology to explore such impacts.
Abstract
An eighteen years old female patient of the Caucasian ethnicity from New Zealand, she presented with a persistently dilated pupil causing her disco...
Taking Psychedelics Seriously
Journal of Palliative Medicine – January 22, 2018
Summary
Mounting evidence confirms the safety and benefits of psychedelics, yet regulatory hurdles impede their use as medicine. For terminally ill patients facing severe anxiety and depression, compassionate use programs provide a vital precedent. Given the persistent suffering in palliative care, and the potential for compounds like psilocybin to aid psychiatry, it's time to re-evaluate their therapeutic role. Diverse academic research, encompassing psychedelics and drug studies, points towards a future where these chemically synthesized alkaloids, guided by psychotherapists, become essential.
Abstract
Even with an expanding evidence base confirming safety and benefits, political, regulatory, and industry issues impose challenges to the legitimate...
Scoping Review: The Role of Psychedelics in the Management of Chronic Pain
Journal of Pain Research – March 01, 2024
Summary
Emerging evidence suggests psychedelics, including psilocybin, hold significant potential in medicine for alleviating chronic pain. This exciting area, explored via MEDLINE and Psychiatry databases, indicates hallucinogens derived from chemical synthesis and alkaloids could offer novel therapeutic avenues. While Complementary and Alternative Medicine Studies highlight promise, robust, randomized, double-blind, placebo-controlled trials are crucial. These Psychedelics and Drug Studies are essential to fully evaluate their role in chronic, non-cancer pain management.
Abstract
Psychedelics may have potential in alleviating pain symptoms secondary to a multitude of chronic pain conditions. However, further randomized, doub...
Serotonergic psychedelic treatment for obesity and eating disorders: potential expectations and caveats for emerging studies
Journal of Psychiatry and Neuroscience – June 01, 2022
Summary
A significant shift in Psychiatry is underway, as serotonergic psychedelics, including the classic hallucinogen Lysergic acid diethylamide, increasingly enter mainstream Medicine. Numerous clinical trials are exploring their potential for major depressive disorder, substance use disorder, and even eating disorders. This burgeoning field within Psychology and Psychedelics and Drug Studies highlights how these compounds, often from chemical synthesis and alkaloids, influence behavior through neurotransmitter receptor interaction, offering new therapeutic avenues.
Abstract
There has been a substantial growth in private clinics and registered clinical trials employing serotonergic psychedelics for various psychiatric i...
Advances in Psychedelic Therapeutics: Multimodal Iboga Analogs, EEG-Guided Psilocybin Dosing, and Optimized Harmine–DMT Formulations
ACS Medicinal Chemistry Letters – December 16, 2025
Summary
Psychedelic medicine is rapidly evolving towards unprecedented precision and personalization. Three key innovations are transforming these therapeutics. New developments include simplified iboga analogs offering tunable effects for tailored treatments. Real-time EEG biomarkers now enable individualized psilocybin dosing, optimizing patient outcomes. Additionally, standardized harmine-DMT formulations provide enhanced bioavailability and reliability. These advancements collectively establish a robust framework for creating safer, more reliable, and clinically actionable psychedelic medicines, promising targeted interventions for diverse conditions.
Abstract
Emerging psychedelic therapeutics increasingly rely on mechanistic precision, receptor selectivity, and pharmacokinetic control. Recent inventions ...
Ketamine Psychedelic Psychotherapy: Focus on its Pharmacology, Phenomenology, and Clinical Applications
International Journal of Transpersonal Studies – July 01, 2014
Summary
Ketamine, a powerful dissociative medicine, is transforming psychiatry's approach to major depression. Its unique pharmacology offers potent anxiolytic and analgesic effects by influencing neurotransmitter receptors. Psychotherapists are exploring its use in Psychedelics and Drug Studies, particularly Ketamine Psychedelic Psychotherapy (KPP). An extensive review of literature details KPP's clinical applications, exploring the phenomenology of transpersonal experiences to guide treatment, drawing on Psychology and Neuroscience. It also highlights potential risks, underscoring its role in modern medicine.
Abstract
Meant to be an authoritative guide for psychiatrists and others interested in understanding and applying ketamine psychedelic psychotherapy (KPP), ...
A Multidisciplinary Hypothesis about Serotonergic Psychedelics. Is it Possible that a Portion of Brain Serotonin Comes From the Gut?
Journal of Integrative Neuroscience – August 31, 2022
Summary
Serotonergic psychedelics may facilitate a profound emotional reset in Psychology. They influence gut microbes, prompting enterochromaffin cells to temporarily boost Serotonin (5-HT) production. This surge, acting hormonally, enhances blood-brain barrier (BBB) permeability. Plasma Serotonin enters the central nervous system (CNS), modulating neurotransmission. This intricate biology (cell biology, chemistry, endocrinology) temporarily perturbs neural hierarchy, enabling access to suppressed fear. This mechanism, central to Neuroscience and Psychedelics and Drug Studies, highlights Neurotransmitter Receptor Influence on Behavior, requiring Biochemical Analysis.
Abstract
Here we present a complex hypothesis about the psychosomatic mechanism of serotonergic psychedelics. Serotonergic psychedelics affect gut microbes ...
Psychedelics: a window into perceptual processing
OpenAlex – September 13, 2024
Summary
Psilocybin-induced visual distortions and impaired executive function originate in temporary disruptions of attentional mechanisms, a key finding for cognitive psychology. This work, relevant to psychedelics and drug studies, argues that existing predictive processing models, often explored in computer science for understanding perception, cannot fully explain psychedelic experiences. Instead, a new "Gist Theory of Perception" is proposed. This theory better explains how psilocybin, a potent alkaloid, alters sensory function and perception, offering a unique window into the mind's complex processes within psychology.
Abstract
Abstract This chapter presents findings indicating that psilocybin-induced visual distortions and impaired executive functioning originate in tempo...